ERBB2 and neoplasm: The dose-dependent tumor shrinkage observed in the HER2+ cell line is negligible in the Triple Negative cell line, suggesting that maximal pharmacodynamic response is achieved at 1 mg/kg, but tumor stabilization is observed when BID or QD schedules are considered.